Abstract: Objective The aim of this study was to investigate the changes of serum chemokine C-C-motif ligand 4 (CCL4) and C-X-C motif chemokine ligand 10 (CXCL10) levels in patients with autoimmune hepatitis (AIH). Methods A total of 72 patients with AIH were enrolled in our hospital between December 2016 and December 2020, and all patients received liver biopsy and standardized treatment recommended by related the guidelines for more than 2 years. Serum chemokines CCL4 and CXCL10 were detected by ELISA. Results At the end of two year treatment, 25 patients got complete response (CR) and 47 patients got incomplete response (IR); serum CCL4 and CXCL10 levels ad admission in patients with CR were (46.4±18.4)pg/ml and (42.2±8.5)pg/ml, significantly lower than [(61.3±22.6)pg/ml and (89.1±47.4)pg/ml, respectively, P<0.05] in patients with IR; the abnormal blood coagulation function tests was found in 26 patients out of our series, and all of them were IR patients; the PT, APTT and TT levels in patients with CR were (11.8±1.3) s, (29.6±2.2) s and (15.6±1.2)s, significantly lower than [(13.9±3.6)s, (41.3±6.2)s and (18.9±1.9)s, respectively, P<0.05], while the FIB was (3.1±0.8)g/l, significantly higher than [(3.7±1.2)g/l, P<0.05] in patients with IR; serum CCL4 and CXCL10 levels in patients with normal blood coagulation function tests were (50.2±16.5)pg/ml and (66.3±18.2)pg/ml, significantly lower than [(68.0±24.2)pg/ml and (85.5±39.7)pg/ml, P<0.05] in patients with abnormal blood coagulation function tests. Conclusion Serum chemokines CCL4 and CXCL10 levels in patients with AIH might predict the response to immunosuppression therapy, which needs further clinical trials to verify it.

Key words: Autoimmune hepatitis, Chemokine C-C-motif ligand 4 , C-X-C motif chemokine ligand 10, Coagulation function, Response